Imatinib: the first 3 years.

European journal of cancer (Oxford, England : 1990)

Volumn 38 Suppl 5, Issue , 2002, Pages

  Capdeville, Renaud ^a   Silberman, Sandra ^a   Dimitrijevic, Sasa ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CHILD; CHRONIC MYELOID LEUKEMIA; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SURVIVAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS;

MLCS; MLOWN;

EID: 0036769771     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(02)80607-4     Document Type: Review

References (31)